Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,819 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: matched control group Clear all

Conditions: Cystic Fibrosis
Interventions: Tezacaftor/Ivacaftor, Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more

Conditions: Autism Spectrum Disorder
Interventions: JNJ-42165279, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 35 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 9
States / cities: Dothan, Alabama • Phoenix, Arizona • Orange, California + 6 more

Conditions: Food Insecurity, Healthy Eating
Interventions: Video tutorial, Delivery fee waiver, Texting, Financial incentive, Grocery list with instant shoppable SNAP-Ed recipes; Behavioral
Lead sponsor: New York University; Other
Eligibility: 2 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Tuberous Sclerosis Complex
Interventions: Early Vigabatrin, Delayed Vigabatrin (Placebo); Drug
Lead sponsor: Martina Bebin; Other
Eligibility: 1 Day to 6 Months
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Physical Activity, Blood Pressure, Physical Functioning, Quality of Life, Sedentary
Interventions: Physical Activity, Group educational sessions, Phone counseling call, Peer Mentoring, Policy Change, Support, Tailored environmental resources, Health check phone call, Pedometer; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 65 Years and older
Enrollment: 307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Migraine
Interventions: Lu AG09222, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more

Conditions: Inflammatory Acne
Interventions: LYS006 20 mg, LYS006 2 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Fremont, California • Santa Monica, California • Hialeah, Florida + 4 more

Conditions: Arthritis, Psoriatic
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more

Conditions: Asthma
Interventions: CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP); Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 134
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more

Conditions: Food Insecurity, Fruit and Vegetable Consumption in Children, Produce Prescription Program Utilization
Interventions: Delivered Produce Prescription, Delivered Healthy Meal Kit, Standard of Care Mobile Market Voucher; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diet, Healthy
Interventions: Control, Ultraprocessed warning label; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 3,645 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Osteoarthritis, Knee, Post-traumatic Osteoarthritis, ACL Tear
Interventions: Metformin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Lexington, Kentucky + 6 more

Conditions: Mycobacterium Infections, Nontuberculous
Interventions: ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS); Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 90
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more

Conditions: Chronic Prostatitis, Chronic Pelvic Pain Syndrome
Interventions: AQX-1125 200 mg, Placebo; Drug
Lead sponsor: Aquinox Pharmaceuticals (Canada) Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 23
States / cities: Homewood, Alabama • Mobile, Alabama • Tucson, Arizona + 19 more

Conditions: Human Immunodeficiency Virus
Interventions: IMB, Information-Only Control; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 17 Years to 24 Years · Male only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Carcinoma
Interventions: Everolimus, Everolimus Placebo, Best Supportive Care (BSC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more

Conditions: Breast Cancer, Breast Benign
Interventions: Breast MRI, Breast Mammogram, Blood draw, Breast Biopsy, online participant reported questionnaire; Device · Other · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 7
States / cities: Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 4 more

Conditions: Meningitis, Meningococcal Disease
Interventions: None administered in this study; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 62,626 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Renal Impairment
Interventions: TR-701 FA single infusion, TR-701 FA; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Lupus Erythematosus, Systemic
Interventions: Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Groundskeeper for ADHD group, Groundskeeper for control group; Device
Lead sponsor: CogCubed, Corp; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 72
States / cities: Foley, Alabama • Mobile, Alabama • Sheffield, Alabama + 62 more

Conditions: Healthy
Interventions: Cold-Pressor Task (CPT), Control CPT, fMRI; Behavioral · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 64 Years
Enrollment: 397 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Takotsubo Syndrome
Interventions: Tako Breath; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

Optimizing Online Purchasing of Fruits, Vegetables, and Legumes for Low-Income Families

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

Multilevel Intervention for Physical Activity in Retirement Communities

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

Pediatric Food is Medicine Study

Testing Ultraprocessed Food Labels in Chile

Preventing Injured Knees From osteoArthritis: Severity Outcomes

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Mobile-health (mHealth) Intervention to Support HIV Self-testing and PrEP Uptake Among Young Men Who Have Sex With Men

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Neural Mechanisms of Cost and Benefit Integration During Decision-Making, Aim 2: Acute & Lifetime Stress

Autonomic Modulation in Takotsubo Syndrome